Protocols and Concepts

Listed below are Moffitt CCOP Research Base studies. Click on the study title to view the protocol/concept status and eligibility requirements.

Active Protocols:

• HLMCC 0402 Oral Glutamic Acid to Decrease Vincristine Toxicity in Children with Cancer (02/04/08)
  
  
• HLMCC 0501 Stress Management Therapy for Patients Undergoing Chemotherapy (02/04/08)
  
  
• HLMCC 0502 Thyroid Function & Breast Cancer: A Pilot Study to Estimate the Prevalence of Thyroid Dysfunction in Women Diagnosed with Breast Cancer and the Magnitude of Change in Thyroid Function Post-Chemotherapy (12/11/06)
  
  
• HLMCC 0503 Phase II Randomized, Double Blinded Study of An Antiemetic Pump, using Benadryl ®, Ativan® and Decadron® (BAD), for Children Receiving Moderately or Highly Emetogenic Chemotherapy (12/16/07)

Pending Protocols:

• HLMCC 0703 Prevention of Cancer/Treatment-Related Weight Loss in Children Receiving Moderate to Highly Emetic Chemotherapy  (01/31/08)
  
  
• HLMCC 0802 An Open Label Randomized Phase II of an Appetite Stimulant, Cyproheptadine Hydrochloride (Periactin®), With and Without a Nutritional Supplement on Weight in Children with Cancer/Treatment-Related Weight Loss (07/14/08)

Concepts:

• A Pilot Project to Determine the Effect of Losartan (Cozaar) on Radiation-Induced Pulmonary Fibrosis in Patients with Non-Small Cell Lung Cancer (02/28/08)
  
  
• HLMCC 0709 Risperidone for the Treatment of Cerebellar Mutism Syndrome: A Randomized, Phase II, Double-Blind, Placebo-Controlled Study (02/04/08)
  
  
• HLMCC 0803 A Randomized, Phase II Placebo-Controlled Study of the Use of Extended-Release Methylphenidate and Modafinil for the Treatment of Excessive Daytime Sleepiness in Children Following Cancer Therapy (08/08/08)
  
  
• HLMCC 0806 A randomized, placebo controlled phase II study of lisinopril and extended-release (ER) carvedilol phosphate for the prevention of trastuzumab-induced cardiotoxicity in breast cancer patients receiving trastuzumab (8/15/08)